← Search & browse all drugs
DERMATOLOGICALS › OTHER DERMATOLOGICAL PREPARATIONS › OTHER DERMATOLOGICAL PREPARATIONS › Other dermatologicals
ivermectin
D11AX22
Forms & Strengths
- Tablets: 3mg, 6mg, 12mg
- Cream: 1% (10mg/g)
- Solution for injection: 1% (10mg/mL)
- Oral solution: 0.8% (8mg/mL)
Adult Dosing
- Onchocerciasis: 150mcg/kg orally every 6-12 months
- Strongyloidiasis: 200mcg/kg orally once, repeat in 2 weeks if needed
- Scabies: 200mcg/kg orally once, repeat in 7-10 days if needed
Pediatric Dosing
- Children >15kg and >5 years: same as adult dose
- Children 15kg and <15kg: 100-150mcg/kg orally for onchocerciasis
- Children <5 years: not recommended, unless benefits outweigh risks
Indications
- Onchocerciasis (river blindness)
- Strongyloidiasis
- Scabies
- Lymphatic filariasis
- Cutaneous larva migrans
Mechanism of Action
- Inhibits glutamate-gated chloride channels in invertebrate nerve and muscle cells
- Increases membrane permeability, leading to paralysis and death of parasites
Contraindications
- Hypersensitivity to ivermectin or any component
- Concomitant use of drugs that prolong QT interval
- History of meningitis or encephalitis caused by Loa loa
Adverse Reactions
- Gastrointestinal: diarrhea, nausea, vomiting
- Neurological: dizziness, headache, somnolence
- Dermatological: pruritus, rash, urticaria
- Ophthalmological: blurred vision, conjunctivitis
Drug Interactions
- Cholinesterase inhibitors: increased risk of toxicity
- Cytochrome P450 3A4 inhibitors: increased ivermectin levels
- Warfarin: increased risk of bleeding due to increased INR
Curated Content: Needs Vetting Before Put to Clinical Use